

Appendix 1: Adult Acute lymphoblastic leukemia (ALL)

Approved settings/ treatment line	Protocols	Evidence level
Adolescents, Ph +ve Induction	TKI + BFM Protocol (Cyclophosphamide, Vincristine, Daunorubicin, Cytarabine, Dexamethasone, Peg-aspargase, Methotrexate, Prednisone)	Category 2A
	TKI + Hyper-CVAD (Hyper-fractionated Cyclophosphamide, Doxorubicin, Vincristine, Dexamethasone alternating with HD Methotrexate, Cytarabine)	Category 2A
	TKI + Corticosteroids.	Category 2A
	TKI + (Cyclophosphamide, Daunorubicin, Vincristine, Prednisone)	Category 2A
	TKI + Vincristine + Dexamethasone.	Category 2A
	CALGB 10701 (Dexamethasone, Vincristine, Cytarabine, Daunorubicin, Methotrexate, Etoposide).	Category 2A
Adult < 65 y, Ph +ve Induction	TKI + Hyper-CVAD (Hyper-fractionated Cyclophosphamide, Doxorubicin, Vincristine, Dexamethasone alternating with HD Methotrexate, Cytarabine).	Category 2A
	TKI + Corticosteroids.	Category 2A
	TKI + (Cyclophosphamide, Daunorubicin, Vincristine, Prednisone)	Category 2A
	TKI + Vincristine + Dexamethasone.	Category 2A
	CALGB 10701 (Dexamethasone, Vincristine, Cytarabine, Daunorubicin, Methotrexate, Etoposide).	Category 2A
Adolescents, Ph -ve Induction	CALGB 10403 (Daunorubicin, Vincristine, Prednisone, Pegaspargase)	Category 2A
	COG AALL 0232 (Daunorubicin, Vincristine, Prednisone, Pegaspargase)	Category 2A
	COG AALL 0434 + Nelarabine in consolidation regimen.	Category 2A
	DFCI ALL (Doxorubicin, Vincristine, Prednisone, HD Methotrexate, Pegaspargase)	Category 2A
	GRAALL-2005 Regimen (Daunorubicin, Vincristine, Prednisone, Pegaspargase, Cyclophosphamide) + Rituximab for CD-20 +ve	Category 2A
	PETHEMA ALL-96 Regimen (Daunorubicin, Vincristine, Prednisone, Pegaspargase, Cyclophosphamide)	Category 2A
	Hyper-CVAD (Hyper-fractionated Cyclophosphamide, Doxorubicin, Vincristine, Dexamethasone alternating with HD Methotrexate, Cytarabine) ± Rituximab.	Category 2A
	USC ALL Regimen (Daunorubicin, Vincristine, Prednisone, Pegaspargase, Methotrexate)	Category 2A
	Linker-4 regimen (Daunorubicin, Vincristine, Prednisone, Pegaspargase)	Category 2A
Adult < 65 y, Ph -ve Induction	CALGB 8811 Regimen (Daunorubicin, Vincristine, Prednisone, Pegaspargase, Cyclophosphamide)	Category 2A
	GRAALL-2005 Regimen (Daunorubicin, Vincristine, Prednisone, Pegaspargase, Cyclophosphamide) + Rituximab for CD-20 +ve	Category 2A
	Hyper-CVAD (Hyper-fractionated Cyclophosphamide, Doxorubicin, Vincristine, Dexamethasone alternating with HD Methotrexate, Cytarabine) ± Rituximab.	Category 2A
	Linker-4 regimen (Daunorubicin, Vincristine, Prednisone, Pegaspargase)	Category 2A
	MRC UKALLXII/ ECOG 2993 Regimen (Daunorubicin, Vincristine, Prednisone, Pegaspargase Induction phase 1) and (Cyclophosphamide, Cytarabine, 6-MP Induction phase 2).	Category 2A
Maintenance	Methotrexate, 6-MP, Vincristine/ Prednisone Monthly pulses	Category 2A
Relapsed/ Refractory Ph +ve	TKIs (may be used in combination with Unused Induction regimen)	Category 2A
	Blinatumomab (TKI Intolerant/ refractory) (B-ALL)	Category 2A
	Inotuzumab ozogamycin (TKI Intolerant/ refractory) (B-ALL)	Category 2A
	MOpAD Regimen (Methotrexate, Vincristine, Pegaspargase, Dexamethasone, TKIs, Rituximab if CD-20 +ve)	Category 2B



Approved settings/ treatment line	Protocols	Evidence level
Relapsed/ Refractory Ph - ve	Blinatumomab (B-ALL)	Category 1, Preferred
	Inotuzumab ozogamycin (B-ALL)	Category 1
	Inotuzumab ozogamycin + Hyper-CVAD (Cyclophosphamide, Dexamethasone, Vincristine, Cytarabine, Methotrexate)	Category 2A
	Augmented Hyper-CVAD Regimen.	Category 2A
	Liposomal Vincristine.	Category 2A
	MOPAD Regimen (Methotrexate, Vincristine, Pegaspargase, Dexamethasone, TKIs, Rituximab if CD-20 +ve)	Category 2A
	Etoposide, Ifosfamide, Mitoxantrone.	Category 2A
	FLAM Regimen: Fludarabine, Cytarabine, Mitoxantrone.	Category 2A
	FLAG-IDA Regimen: Fludarabine, Cytarabine, CSF ± Idarubicin.	Category 2A